BTLA Protein, Human, Recombinant (hFc)

Catalog No. TMPY-00175

BTLA Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 38.8 kDa and the accession number is Q7Z6A9-2.

BTLA Protein, Human, Recombinant (hFc)

Catalog No. TMPY-00175

BTLA Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 38.8 kDa and the accession number is Q7Z6A9-2.

Pack Size	Price	Availability	Quantity
100 μg	$600	7-10 days
1 mg	$3,910	7-10 days

Bulk & Custom

Add to Cart

Questions

Resource Download

User Guide of Recombinant Proteins

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Information

Biological Activity	1.Measured by its binding ability in a functional ELISA.2. Immobilized human BTLA-Fc at 10μg/mL (100μL/well) can bind biotinylated mouse HVEM-Fch , the EC50 of biotinylated mouse HVEM-Fch is 6-70 ng/mL. 3.Loaded Recombinant Human HVEM Protein, hFc Tag on AR2G Biosensor, can bind Recombinant Human BTLA protein, hFc Tag with an affinity constant of 52.6 nM as determined in BLI assay (Routinely tested).
Description	BTLA Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 38.8 kDa and the accession number is Q7Z6A9-2.
Species	Human
Expression System	HEK293 Cells
Tag	C-hFc
Accession Number	Q7Z6A9-2
Synonyms	CD272,BTLA1,B and T lymphocyte associated
Construction	A DNA sequence encoding the human BTLA (NP_001078826.1) (Met1-Thr134) was expressed with the Fc region of human IgG1 at the C-terminus. Predicted N terminal: Lys 31
Protein Purity	> 90 % as determined by SDS-PAGE
Molecular Weight	38.8 kDa (predicted); 53.7 kDa (reducing condition, due to glycosylation)
Endotoxin	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
Reconstitution	A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.
Stability & Storage	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	In general, Lyophilized powders are shipping with blue ice.
Research Background	BTLA is a inhibitory molecule which belongs to the Ig superfamily. It down-modulates immune responses. As such, reagents that regulate the binding of BTLA to its ligand or alter BTLA signaling have significant therapeutic promise. BTLA is crucial to understand the mechanism(s) of action of these antibodies before attempting clinical applications. BTLA is not expressed by naive T cells, but it is induced during activation and remains expressed on T helper type 1 (T(H)1) but not T(H)2 cells. BTLA is a third inhibitory receptor on T lymphocytes with similarities to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1).Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint TargetsImmunotherapyTargeted Therapy